OMERS ADMINISTRATION Corp Takes $527,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS)

OMERS ADMINISTRATION Corp purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 20,500 shares of the company's stock, valued at approximately $527,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NAMS. JPMorgan Chase & Co. lifted its position in shares of NewAmsterdam Pharma by 176.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company's stock worth $371,000 after purchasing an additional 14,280 shares during the last quarter. Legal & General Group Plc lifted its holdings in NewAmsterdam Pharma by 24.8% during the 4th quarter. Legal & General Group Plc now owns 22,946 shares of the company's stock worth $590,000 after buying an additional 4,556 shares during the last quarter. American Century Companies Inc. purchased a new stake in NewAmsterdam Pharma during the 4th quarter worth about $8,907,000. Swiss National Bank increased its stake in NewAmsterdam Pharma by 105.1% in the fourth quarter. Swiss National Bank now owns 72,000 shares of the company's stock valued at $1,850,000 after purchasing an additional 36,900 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in NewAmsterdam Pharma during the fourth quarter worth approximately $80,000. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS traded down $0.23 on Thursday, reaching $18.28. The company's stock had a trading volume of 340,597 shares, compared to its average volume of 634,151. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29. The stock has a market capitalization of $2.01 billion, a P/E ratio of -9.72 and a beta of 0.01. The stock's 50-day moving average is $18.81 and its two-hundred day moving average is $21.24.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The business had revenue of $2.98 million during the quarter, compared to analysts' expectations of $1.46 million. Equities analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NAMS. Needham & Company LLC dropped their target price on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Wall Street Zen downgraded shares of NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a research note on Thursday. Scotiabank lifted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research report on Thursday, February 27th. Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Finally, UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to MarketBeat.com, NewAmsterdam Pharma currently has an average rating of "Moderate Buy" and an average price target of $43.00.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper acquired 4,005 shares of the stock in a transaction on Tuesday, March 4th. The shares were bought at an average price of $21.02 per share, with a total value of $84,185.10. Following the acquisition, the director now owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. This trade represents a 0.13% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. The trade was a 90.91% decrease in their position. The disclosure for this sale can be found here. Company insiders own 20.84% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.